Drug Trial Radar · NCT07832123
Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Mar 2027
Primary completion
Mar 2029
Study completion Sep 2029
Sponsor
- Lead sponsor
- University of ZurichAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Nuvation Bio Inc.; University Hospital, Zürich
- First posted
- Sep 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The precise positioning of the emerging group of pharmacological inhibitors of mutant IDH enzymes remains to be refined by further studies and defined in national and international guidelines. The present study shall help to close this important knowledge gap when trying to define the role of mutant IDH inhibitors in the treatment algorithms for patients with IDH-mutant WHO grade 3 gliomas. Safusidenib is a novel, oral, potent, brain penetrant inhibitor of mutant IDH1. It has shown high blood brain barrier penetration in both pre-clinical and clinical studies and demonstrated anti-tumor activity with complete or partial responses. We aim at demonstrating the efficacy of safusidenib in patients with newly diagnosed IDH1-mutant CNS WHO grade 3 oligodendroglioma and astrocytoma, measured by progression-free survival at12 months.
Conditions
- Glioma : Oligodendroglioma or Astrocytoma
Interventions
SafusidenibDrug
All participants will receive safusidenib (250 mg BID) until progression or unacceptable toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- progression-free survival at12 monthsTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital Zürich
Zurich, Canton of Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.